VLST-007 addresses primary mechanisms of immune complexes and macrophage/granulocyte activation that are not currently addressed by existing therapeutics.

Preclinical studies of VLST-007 have demonstrated the ability of this therapeutic candidate to inhibit cytokine secretion from activated human dendtiric cells. It has also shown positive effect on joint histopathology compared to control.

The demonstration that VLST-007 can modulate immune-complex mediated inflammation is significant because:

• There are currently few therapeutics in development aimed at modulating this inflammatory pathway.
• There are substantial number of automimmune indications where immune complexes are believed to play a significant role in disease pathology.

Potential clinicial applications for VLST-007 include rheumatoid arthritis, SLE, sjogren's syndrome, clomerulonephritis, vasculitides, cryoglobulenemia, ITP and AIHA.